Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: Maintaining efficacy with less toxicity

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 345-353

  Bartelink, I H ^a,b   van Reij, E M L ^a   Gerhardt, C E ^a   van Maarseveen, E M ^a   de Wildt, A ^a   Versluys, B ^a   Lindemans, C A ^a   Bierings, M B ^a   Boelens, Jaap Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Busulfan; Fludarabine; Hematopoietic cell transplantation; Pediatrics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS INFECTION; ADOLESCENT; ADULT; ARTICLE; CELL SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG INJURY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; VEIN OCCLUSION; WHOLE BODY RADIATION; YOUNG ADULT;

BUSULFAN; FLUDARABINE; HEMATOPOIETIC CELL TRANSPLANTATION; PEDIATRICS;

ADENOVIRIDAE INFECTIONS; ADOLESCENT; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LUNG; MALE; MYELOABLATIVE AGONISTS; ROSEOLOVIRUS INFECTIONS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84896853949     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.027     Document Type: Article

References (67)

1. Shah A.J., Lenarsky C., Kapoor N., et al. Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. JPediatr Hematol Oncol 2004, 26:91-97.
2. Sandler E.S., Hagg R., Coppes M.J., et al. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol 2000, 35:403-409.
3. Izaki S., Goto H., Okuda K., et al. Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. Int J Hematol 2007, 86:253-260.
4. McCune J.S., Holmberg L.A. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009, 5:957-969.
5. McCune J.S., Gooley T., Gibbs J.P., et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 30:167-173.
6. Bartelink I.H., Bredius R.G., Belitser S.V., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:231-241.
7. DeLeve L.D., Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000, 60:143-154.
8. Hassan Z., Hellstrom-Lindberg E., Alsadi S., et al. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells invitro and invivo. Bone Marrow Transplant 2002, 30:141-147.
9. Gandhi V., Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41:93-103.
10. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
11. Chae Y.S., Sohn S.K., Kim J.G., et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007, 40:541-547.
12. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
13. Liu H., Zhai X., Song Z., et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. JHematol Oncol 2013, 6:15.
14. Lee J.H., Joo Y.D., Kim H., et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. JClin Oncol 2013, 31:701-709.
15. Güngör T., Schanz U., Seger R., et al. Successful half-dose busulfan/full-dose fludarabine-based reduced-intensity conditioning in high-risk pediatric and adult chronic granulomatous disease (CGD) patients. Biol Blood Marrow Transplant 2010, 16:S181-S182.
16. Lee J.W., Kang H.J., Lee S.H., et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant 2012, 18:944-950.
17. Pulsipher M.A., Boucher K.M., Wall D., et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009, 114:1429-1436.
18. Tse W.T., Duerst R., Schneiderman J., et al. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 2009, 44:145-156.
19. Law J., Cowan M.J., Dvorak C.C., et al. Busulfan, fludarabine, and alemtuzumab as a reduced-toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 2012, 18:1656-1663.
20. Horn B., Baxter-Lowe L.A., Englert L., et al. Reduced-intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006, 37:263-269.
21. Styczynski J., Tallamy B., Waxman I., et al. Apilot study of reduced-toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011, 46:790-799.
22. Sterkenburg M.J., Boelens J.J., Beelen K., Beelen K. TRIASUS: a Web-based information management system for sharing pre- and post-transplantation clinical, HLA and chimaerism data [abstract]. Biol Blood Marrow Transplant 2009, 15:98.
23. Nath C.E., Earl J.W., Pati N., et al. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2008, 66:50-59.
24. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:472-479.
25. Gaziev J., Nguyen L., Puozzo C., et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010, 115:4597-4604.
26. Cremers S., Schoemaker R., Bredius R., et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002, 53:386-389.
27. Zwaveling J., Bredius R.G., Cremers S.C., et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005, 35:17-23.
28. Bartelink I.H., Bredius R.G., Ververs T.T., et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:88-98.
29. Proost J.H., Meijer D.K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992, 22:155-163.
30. Bartelink I.H., Boelens J.J., Bredius R.G.M., et al. Body weight-dependent pharmacokinetics of busulfan in pediatric hematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 2012, 51:331-345.
31. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
32. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
33. Russell J.A., Duan Q., Chaudhry M.A., et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008, 14:888-895.
34. Corbacioglu S., Cesaro S., Faraci M., et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012, 379:1301-1309.
35. Bartelink I.H., Wolfs T., Jonker M., et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother 2013, 57:235-240.
36. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
37. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995, 85:3005-3020.
38. Thoemes F. Propensity score matching in SPSS. Available from:. Accessed May 2013. http://arxiv.org/ftp/arxiv/papers/1201/1201.6385.pdf.
39. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.
40. Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012, 47:749-756.
41. Iravani M., Evazi M.R., Mousavi S.A., et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant 2007, 40:105-110.
42. Horwitz M.E., Morris A., Gasparetto C., et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008, 14:591-594.
43. Parmar S., Rondon G., de Lima M., et al. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant 2013, 19:474-480.
44. Gajewski J.L., Johnson V.V., Sandler S.G., et al. Areview of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008, 112:3036-3047.
45. Bouligand J., Boland I., Valteau-Couanet D., et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003, 32:979-986.
46. de Pagter P.J., Schuurman R., Visscher H., et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008, 14:831-839.
47. de Pagter P.J., Schuurman R., Keukens L., et al. Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. Bone Marrow Transplant 2013, 48:1460-1464.
48. Bainton R.D., Byrne J.L., Davy B.J., Russell N.H. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002, 100:3843-3844.
49. Lazzarino M., Orlandi E., Baldanti F., et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol 1999, 107:877-882.
50. + cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012, 156:656-666.
51. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
52. Ljungman P., Hassan M., Bekassy A.N., et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997, 20:909-913.
53. Malar R., Sjoo F., Rentsch K., et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant 2011, 15:580-588.
54. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
55. Vassal G., Esperou H., Valteau-Couanet D., et al. Anew I.V. busulfan fixed dosing as part of BuMel or BuCy conditioning regimens: a pharmacokinetic/pharmacodynamic study in pediatric patients undergoing autologous or allogeneic hematopoietic stem cell transplantation. EBMT 2006, 32nd Annual Meeting of the European Group for Blood an Marrow Transplantation, p 770, Physicians Poster Session.
56. Vassal G., Koscielny S., Challine D., et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996, 37:247-253.
57. Long-Boyle J.R., Green K.G., Brunstein C.G., et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 2011, 46:20-26.
58. Valdez B.C., Murray D., Nieto Y., et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leuk Lymphoma 2012, 53:973-981.
59. Valdez B.C., Li Y., Murray D., et al. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011, 81:222-232.
60. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine+/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
61. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
62. Russell J.A., Irish W., Balogh A., et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16:509-514.
63. Kang B.W., Moon J.H., Chae Y.S., et al. Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. Acta Haematol 2010, 123:242-247.
64. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
65. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
66. Oyekunle A., Klyuchnikov E., Ocheni S., et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011, 126:30-39.
67. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy with azacitidine versus induction chemotherapy and post-transplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.